

FORM PTO-1449 (REV. 7-88)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079CON4		SERIAL NO.: 10/056,348	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Ronald BURCH et al.			
				FILING DATE: January 25, 2002		GROUP: 1639	

OIP
 NOV 08 2004
 PATENT & TRADEMARK OFFICE


U.S. PATENT DOCUMENTS									
*EXAMINE R INITIAL	AA	AB	AC	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS									
AD		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
								Yes	No

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)		
	AE	Purdue Discovery Research, Department of Neuropharmacology Study Report "Assessment of the Effects of Combined Administration of Oxycodone and Cox II inhibitors, Celecoxib, Etodolac and Rofecoxib, in the Rat FCA Model of Inflammatory Pain"; July 28, 2003
	AF	
	AG	
	AH	
	AI	
	AJ	
	AK	
	AL	
	AM	
	AN	
	AO	
	AP	
	AQ	
	AR	
	AS	

EXAMINER		DATE CONSIDERED <div style="text-align: right; font-size: 1.2em;">11/7/05</div>
----------	--	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079CON4		SERIAL NO.: 10/056,348	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Ronald BURCH et al.			
				FILING DATE: January 25, 2002		GROUP: 1639	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							Yes No
	AG						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
/	AH	Tanaka et al., "Pharmacological Studies of the New Antiinflammatory Agent 3-Formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one," <i>Arzneim-Forsch/Drug res.</i> 42 (II), Nr. 7, pp. 935-944 (1992)					
	AI	Engelhardt et al., "Anti-inflammatory, Analgesic, Antipyretic and Related Properties of Meloxicam, a New Non-steroidal Anti-inflammatory Agent with Favorable Gastrointestinal Tolerance," <i>Inflamm. Res.</i> 44:423-433 (1995)					
	AJ	Engelhardt, "Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2," <i>Brit. J. Rheumatology</i> 1996:35 (suppl. 1): 4-12					
	AK	Distel et al., "Safety of Meloxicam: A Global Analysis of Clinical Trials," <i>Brit. J. Rheumatology</i> 1996:35 (suppl. 1):68-77					
	AL	Wojtulewski et al., "a Six Month Double-blind Trial to Compare the Efficacy and Safety of Meloxicam 7.5 mg Daily and Naproxen 750 mg Daily in Patients with Rheumatoid Arthritis," <i>Brit. J. Rheumatology</i> 1996:35 (suppl. 1):22-28					
	AM	Swingle et al., "Preclinical Pharmacological Studies With Nimesulide," <i>Drugs Exptl. Clin. Res. Vol. X</i> (8-9) pp. 587-597					
	AN	Rabasseda, "Nimesulide: A Selective Cyclooxygenase 2 inhibitor Antiinflammatory Drug," <i>Drugs of Today Vol 32, No.5</i> (1996), p9. 365-384					
	AO	Siebert et al., "Pharmacological and Biochemical Demonstration of the Role of Cyclooxygenase 2 In Inflammation and Pain," <i>PNAS USA Vol.91</i> (Dec. 1994) pages 12013-12-17					
/	AP	Richardson et al., "The Clinical Implications of Inhibition of the Inducible Form of Cyclo-oxygenase," <i>Drug Safety Vol. 15(4)</i> , pp. 249-260 (Oct. 1996)					
	AQ						
EXAMINER					DATE CONSIDERED 11/7/05		
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>							